Background & Objective: Non-alcoholic fatty liver disease (NAFLD) is a prevalent condition characterized by hepatic fat accumulation, which can progress fibrosis and cirrhosis. Serum ferritin has been proposed as a biomarker for liver disease, but its relationship with fibrosis severity in NAFLD remains unclear. This study explored the relationship between serum ferritin levels and liver fibrosis severity in NAFLD patients. Methods: In this cross-sectional study, 204 NAFLD patients were enrolled, including 139 with mild fibrosis and 65 with severe fibrosis. Baseline and demographic characteristics were compared between groups. Serum ferritin and other biochemical parameters were measured. Logistic regression analyses assessed the predictive value of serum ferritin levels for liver fibrosis severity, and a receiver operating characteristic (ROC) curve determined the optimal ferritin cutoff for identifying sever fibrosis. Results: Patients with severe fibrosis had significantly higher serum ferritin levels than those with mild fibrosis (197.70 ± 79.40 vs 95.70 ± 73.20, P<0.001). Logistic regression analysis confirmed a significant association between ferritin levels and fibrosis severity (OR = 1.015, 95% CI = 1.009-1.02, P<0.001). ROC analysis showed that ferritin distinguished severe from mild fibrosis with 80% sensitivity and 80% specificity at a cutoff of 129 ng/ml (AUC = 0.86). Conclusion: Elevated serum ferritin levels are associated with more severe liver fibrosis in NAFLD patients, supporting ferritin's potential as a non-invasive biomarker for fibrosis severity. Further studies are needed to validate these findings and explore ferritin's diagnostic and prognostic utility in diverse populations.
Memar et al. (Thu,) studied this question.